Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 265, Issue -, Pages 18-23Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2018.04.126
Keywords
Trimethylamine N-oxide; Plaque vulnerability; Thin-cap fibroatheroma; Fibrous cap thickness; Optical coherence tomography
Categories
Funding
- National Natural Science Foundation of China [81330033, 81571749, 81703502]
Ask authors/readers for more resources
Background: Plaque vulnerability indicates the risk of a cardiovascular event. In the present study, we sought to analyze the relationship between trimethylamine N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, and vulnerable plaque characteristics in patients with coronary artery disease (CAD). Methods: One hundred eighty non-culprit plaques from 90 patients with ACS or with stable angina were assessed by optical coherence tomography (OCT). The plasma TMAO levels were measured using rapid resolution liquid chromatography quadrupole time-of-flight mass spectrometry (RRLC-QTOF/MS). Results: Patients were divided into two groups (high TMAO group and low TMAO group) according to the median plasma TMAO level (114.73 mu g/L). The non-culprit plaques in the high TMAO group exhibited a thinner fibrous cap thickness (FCT) (65.97 +/- 25.89 vs. 93.0 +/- 28.28 mu m, P < 0.001), higher frequency of microvessels (75.6% vs. 31.1%, P < 0.001, per-patient) and increased incidence of thin-cap fibroatheroma (TCFA) (69.2% vs. 18.4%, P < 0.001, per-patient) compared with the low TMAO group. Moreover, the level of TMAO was negatively associated with FCT (r = -0.418, P < 0.001). Furthermore, multivariate regression analysis results showed that TMAO (OR: 7.455, 95% CI: 2.753-20.189, P < 0.001) had a significant association with TCFA, with a cut-off point of 118.34 mu g/L, specificity of 72.6% and sensitivity of 79.5% in predicting the prevalence of TCFA. Conclusions: In conclusion, these findings suggest that the level of TMAO is significantly correlated with the incidence of TCFA. New biomarkers acquired through non-invasive means, such as TMAO, offer the potential to improve risk stratification and clinical management in patients with CAD. (C) 2018 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available